EXPO (Research & advisory firms) Stock Valuation & Fair Value Poor on forward returns
EXPO (Research & advisory firms) trades at a current P/E of 34.3, about 6% above its historical normal valuation, with a forward growth estimate of 10.7% and a PEG of 3.21. Analysts' one-year estimates have been hit 73% of the time. Priced at its historical normal P/E of 32.3 on the same blended earnings, the 2026-10-23 close of $77.43 corresponds to about $73.00 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is EXPO overvalued?
At a current P/E of 34.3 versus its historical normal P/E of 32.3, EXPO trades about 6% above its typical valuation, with a PEG of 3.21 on 10.7% forward growth. tickerseer currently rates it poor on forward returns.
What is EXPO's fair value and PEG?
EXPO trades at a current P/E of 34.3 against a historical normal P/E of 32.3, a PEG of 3.21, and a forward growth estimate of 10.7%. Priced at its historical normal P/E of 32.3 on the same blended earnings, the 2026-10-23 close of $77.43 corresponds to about $73.00 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of EXPO changed?
tickerseer's rating has been poor on forward returns since 2026-10-24.
Industry: Research & advisory firms. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.